Phase II antiemetic agent belonging to the new class of NK-1 antagonists indicated for the prevention of Chemotherapy Induced Nausea and Vomiting (CINV).

Study development plan:

• start of phase II studies planned for 3rd Q of 2007 and end scheduled for 4th Q 2008
• start of phase III trials expected in 1st Q 2009.